Skip to content

FGFR2/3-Altered Intrahepatic Cholangiocarcinoma: A Distinct Clinicopathologic and Molecular Subtype Associated with Improved Disease-Specific Survival.

Oct 2026 · Modern Pathology · pp. 101094 · 0 citations · 59 references
Medicine

Abstract

Intrahepatic cholangiocarcinoma (iCCA) is an aggressive neoplasm with a poor prognosis. Fibroblast Growth Factor Receptor (FGFR) has emerged as a therapeutic target; however, the clinicopathologic, molecular, and prognostic features of FGFR-altered iCCAs remain incompletely defined. Thus, a 5-year retrospective study of genomically profiled iCCAs using dual whole-exome and whole-transcriptome sequencing, stratified by FGFR2/3 alteration status, to examine their clinicopathologic characteristics, biomarker expression, molecular profile, and prognostic significance on overall (OS), metastasis-free (MFS), progression-free (PFS), and disease-specific survival (DSS) was performed. Ninety iCCAs (25 [27.8%] FGFR2/3-altered and 65 [72.2%] FGFR2/3-wild-type) were identified. FGFR2/3-altered iCCAs encompassed FGFR2 fusions (BICC1, AHCYL1, CREB5, NOL4, NRAP, PAH, POC1B, SH3GLB1, BAIAP2L1, FKBP15, LRRFIP2, and TNS3), FGFR3::TACC3 fusion, and FGFR2 mutations (C382R and Y375C). FGFR2/3-altered iCCA patients were significantly younger (median = 61.0 vs. 68.0 years; p = 0.014), with larger (median = 9.6 vs. 6.4 cm; p = 0.002), well-differentiated (24.0% vs. 1.5%; p < 0.001), non-mucin-producing (84.0% vs. 3.1%; p < 0.001), and small duct tumors (100% vs. 32.3%; p < 0.001), harboring higher BAP1 (36.0% vs. 12.3%; p = 0.016), lower TP53 mutations (4.0% vs. 26.2%; p = 0.019), and ARID1A/KRAS wild-type (0.0% and 0.0% vs. 20% and 13.8%; p = 0.016 and 0.058). FGFR2/3-wild-type iCCAs were TP53/KRAS-enriched and harbored rare fusions (ST7::MET, NRG1::RBPMS, and RAB3GAP2::BRAF). FGFR2/3-altered iCCA patients had significantly higher 1-, 2-, and 3-year DSS (95.8%, 79.1%, and 79.1% vs. 68.4%, 48.2%, and 43.8%; univariate analysis: HR 0.29; 95% CI 0.09-0.95; p = 0.041) but not on multivariate analysis (HR 2.52; 95% CI 0.14-45.07; p = 0.530). In small duct iCCAs, FGFR2/3-altered iCCAs maintained significantly higher DSS versus their wild-type counterparts (95.8%, 79.1%, and 79.1% vs. 60.5%, 32.3%, and 32.3%; HR 0.24; 95% CI 0.06-0.90; p = 0.022), indicating improved survival is attributed to factors beyond small duct subtype. Independent prognostic factors included tumor multifocality (lower MFS), CEA > 2.5 ng/mL (lower PFS), TP53 mutation (lower OS), KRAS mutation (lower OS and DSS), radiotherapy (higher OS), and surgical resection (higher OS, MFS, and DSS). FGFR2/3-altered iCCAs represent a distinct subtype associated with improved DSS, driven by inherent clinicopathologic and co-molecular characteristics rather than FGFR2/3 alteration status alone. Genomic profiling expands the molecular landscape of iCCAs, refines prognostication, and informs patient selection for targeted therapy.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.